Skip to main content

Media Category: x - Recorded Webinars

Prognostic Factors for Evaluation of MS Therapy in Treatment Naive Patients

Written by ParadigMS Foundation on .

Magd Zakaria presented a clinically oriented approach to integrating prognostic factors into early treatment decision-making in Multiple Sclerosis (MS). Building on current evidence and international guidelines, this keynote addresses a central question in MS management: how to balance early use of high-efficacy therapies with individual disease activity, patient characteristics, and healthcare system constraints. Key Insights from the Lecture: Disability progression in MS is primarily driven by progression independent of relapse activity (PIRA), which begins early in the...

Continue reading

Pregnancy and Lactation in Multiple Sclerosis

Written by ParadigMS Foundation on .

Family planning is a core part of care in Multiple Sclerosis (MS), particularly because many patients are women of reproductive age. This webinar reviews the clinical considerations around conception, pregnancy, postpartum relapse risk, breastfeeding, and treatment selection. It also addresses how disease-modifying therapies can be used before, during, and after pregnancy to support both maternal disease control and informed reproductive decision-making. Learning Objectives After this webinar, participants should be able to: Explain why family planning should be discussed early...

Continue reading

MRI and the implications of the new diagnostic criteria

Written by ParadigMS Foundation on .

This webinar provides an expert overview of the revised diagnostic criteria for Multiple Sclerosis (MS), with a specific focus on their implications for magnetic resonance imaging (MRI) in clinical practice. Building on the 2017 framework, the updated criteria aim to improve diagnostic specificity while enabling earlier and more accurate identification of MS. The session reviews the key changes, including the introduction of new topographies and MRI biomarkers, and discusses how these elements can be integrated into routine clinical workflows. Through expert insights and clinical...

Continue reading

The Clinical Management of NMOSD in Belgium

Written by ParadigMS Foundation on .

Neuromyelitis optica spectrum disorder (NMOSD) is a rare but severe neuroinflammatory disease requiring rapid diagnosis and prompt treatment to prevent irreversible disability. In this expert-led webinar, Vincent van Pesch explores the latest advances in NMOSD diagnosis and management, with a particular focus on clinical practice in Belgium. The webinar is introduced and moderated by Melissa Cambron. The session covers diagnostic red flags, imaging features, antibody testing, and evolving therapeutic strategies that are reshaping patient care. Learning Objectives After...

Continue reading

Real Life Experiences with Biosimilars

Written by ParadigMS Foundation on .

This expert-led webinar explored real-world experience with biosimilars in the treatment of Multiple Sclerosis (MS), with a particular focus on biosimilar natalizumab. Organized by ParadigMS, the session brought together Jelena Drulovic and Tjalf Ziemssen to discuss regulatory principles, clinical evidence, and practical challenges encountered in daily neurological practice. Professors reviewed the scientific and regulatory framework for biosimilars, emphasizing the concept of “totality of evidence” required for approval, including analytical, functional, pharmacokinetic,...

Continue reading

Astrocytes and myelin – pathology and pathway

Written by ParadigMS Foundation on .

Advances in antibody testing and biomarker-driven diagnostics have reshaped the distinction between Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), and MOG antibody-associated disease (MOGAD). Florian Deisenhammer reviews the historical shift from considering NMO a subtype of MS to recognizing NMOSD as a distinct antibody-mediated condition, and outlines how AQP4-IgG and MOG-IgG testing – together with characteristic MRI and CSF patterns – supports more accurate diagnosis. A central message is that these diseases can overlap clinically, but...

Continue reading

FAQs

Is ParadigMS for free?

Yes, a ParadigMS subscription is free for healthcare practitioniers. 

Do subscriptions auto-renew?
Your subscription will automatically renew on yearly basis. If you cancel your plan, it will not renew at the end of your subscription cycle. 
I am a representative from industry, can I subscribe?

Free subscriptions to ParadigMS are reserved for healthcare practitioners. If you are a representative of the industry please contact us on learning@paradigms.foundation and we would advise you how to get the access to the material. 

What happens if I subscribe as a HCP if I am not?
If you subscribe as a healthcare practitioner and it is proven that you are not a healthcare practitioner, we will cancel your subscription immediately. 
I am a patient, can I subscribe?

ParadigMS is designed specifically for healthcare practitioners, with content and language tailored to their professional needs. While patients cannot subscribe directly, we encourage you to consult your healthcare provider for relevant insights and updates that may benefit you.

Why should I subscribe to ParadigMS's e-platform?

Subscribing to ParadigMS’s e-platform gives you access to up-to-date information and valuable learning materials on multiple sclerosis and NMO, along with expert insights and the latest innovations in the field. It’s an essential resource for staying informed and enhancing your knowledge in MS care.

How can I cancel my subscription?
You can cancel your subscription in your account settings. 
Can I financially support ParadigMS?

Yes, you can financially support ParadigMS! We welcome donations to help us continue our mission of advancing multiple sclerosis education and research. Your contribution directly supports the creation of educational resources, expert discussions, and innovative projects in MS care. Visit our donation page to learn more about how you can make a difference: ParadigMS Donate.